Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force

Eu Jeong Ku1,*, Kyoung Jin Kim2,3,*, Jung Hee Kim4, Mi Kyung Kim5, Chang Ho Ahn6, Kyung Ae Lee7, Seung Hun Lee8, You-Bin Lee9, Kyong Hye Park10, Yun Mi Choi11, Namki Hong12, A Ram Hong13, Sang-Wook Kang13, Byung Kwan Park14, Moon-Woo Seong15, Myungshin Kim16, Kyeong Cheon Jung17, Chan Kwon Jung18, Young Seok Cho19, Jin Chul Paeng20, Jae Hyeon Kim9, Ohk-Hyun Ryu21, Yumie Rhee2, Chong Hwa Kim22, Eun Jig Lee2

1Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju; 2Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine; 3Department of Medicine, Korea University College of Medicine; 4Division of Endocrinology and Metabolism, Department of Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul; 5Department of Internal Medicine, Keimyung University School of Medicine, Daegu; 6Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam; 7Division of Endocrinology and Metabolism, Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju; 8Division of Endocrinology and Metabolism, Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine; 9Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; 10Division of Endocrinology and Metabolism, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang; 11Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong; 12Department of Internal Medicine, Chonnam National University Medical School, Gwangju; 13Thyroid-Endocrine Surgery Division, Department of Surgery, Yonsei University College of Medicine; 14Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine; 15Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine; 16Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea; 17Department of Pathology, Seoul National University College of Medicine; 18Department of Hospital Pathology, College of Medicine, The Catholic University of Korea; 19Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine; 20Department of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul; 21Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon; 22Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong General Hospital, Bucheon, Korea

Received: 9 November 2020, Revised: 19 January 2021, Accepted: 15 February 2021

Corresponding authors: Chong Hwa Kim
Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong General Hospital, 28 Hohyeon-ro 489beon-gil, Sosa-gu, Bucheon 14754, Korea
Tel: +82-32-340-1116, Fax: +82-32-340-1236, E-mail: drangel@sejongh.co.kr

Eun Jig Lee
Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-2228-1983, Fax: +82-2-393-6884, E-mail: ejlee423@yuhs.ac

*These authors contributed equally to this work.

Copyright © 2021 Korean Endocrine Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pheochromocytoma and paraganglioma (PPGLs) are rare catecholamine-secreting neuroendocrine tumors but can be life-threatening. Although most PPGLs are benign, approximately 10% have metastatic potential. Approximately 40% cases are reported as harboring germline mutations. Therefore, timely and accurate diagnosis of PPGLs is crucial. For more than 130 years, clinical, molecular, biochemical, radiological, and pathological investigations have been rapidly advanced in the field of PPGLs. However, performing diagnostic studies to localize lesions and detect metastatic potential can be still challenging and complicated. Furthermore, great progress on genetics has shifted the paradigm of genetic testing of PPGLs. The Korean PPGL task force team consisting of the Korean Endocrine Society, the Korean Surgical Society, the Korean Society of Nuclear Medicine, the Korean Society of Pathologists, and the Korean Society of Laboratory Medicine has developed this position statement focusing on the comprehensive and updated diagnosis for PPGLs.

**Keywords:** Pheochromocytoma; Paraganglioma; Diagnosis; Classification

---

**SUMMARY**

1. **New classification of pheochromocytoma/paraganglioma**
   1.1. All pheochromocytoma and paraganglioma (PPGLs) are considered to have metastatic potential. The terms “benign” and “malignant” should not be used to distinguish non-metastatic PPGLs from metastatic PPGLs (A).
   1.2. The tumor-node-metastasis (TNM) staging system should be evaluated in diagnosing PPGLs (A).

2. **Biochemical tests of pheochromocytoma/paraganglioma**
   2.1. Initial biochemical tests of PPGL should include measurements of plasma free metanephrines or urinary fractionated metanephrines (A).
   2.2. Measurements of urinary dopamine and plasma 3-methoxytyramine are useful for the biochemical diagnosis of PPGLs with predominantly dopamine secretion and/or high risk for metastases (C).
   2.3. Chromogranin A can be used as a biomarker for biochemically silent PPGL (PPGL with normal metanephrine, normetanephrine, and 3-methoxytyramine) (C).

3. **Imaging of pheochromocytoma/paraganglioma**
   3.1. Once there is clear biochemical evidence of a PPGL, anatomic imaging by computed tomography (CT) is the first-choice imaging modality to locate PPGLs. Magnetic resonance imaging is the second-choice imaging method when CT findings are inconclusive or when patients are poor candidates to undergo contrast-enhanced CT (A).
   3.2. Functional imaging is recommended for evaluating disease characteristics and detecting metastases, particularly in patients with a high-risk for metastases and multifocal diseases (e.g., larger tumor size >5.0 cm, extra-adrenal, bilateral, or hereditary) (A).
   3.3. We suggest $^{123}$I-metaiodobenzylguanidine (MIBG) scintigraphy/single-photon emission computed tomography (SPECT), gallium 68 ($^{68}$Ga) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-somatostatin receptor analogs (SSA) positron emission tomography (PET)/CT, or fluorine-18-L-dihydroxyphenylalanine ($^{18}$F-DOPA) PET/CT as the functional imaging modality according to the genotype, location, availability of radiopharmaceuticals, and clinical situation (B).
   3.4. In PPGL patients planning for $^{131}$I-MIBG treatment, $^{123}$I-MIBG is necessary for treatment decision and response monitoring. $^{68}$Ga-DOTA-SSA PET/CT is necessary in patients with metastatic PPGLs when peptide receptor radionuclide therapy (PRRT) is planned (B).
INTRODUCTION

Pheochromocytomas and paragangliomas (PPGLs) are rare chromaffin cells-derived tumors that originated from the adrenal medulla and the extra-adrenal sympathetic or parasympathetic paraganglia, respectively. The overall annual incidence of PPGLs is estimated to be two to eight cases per million, and the recent report in Korea showed the annual incidence of 1.8 cases per million [1-4].

PPGLs release catecholamines, mainly norepinephrine and epinephrine, causing hypertension, headache, sweating, and palpitations. If not recognized, PPGLs can severely affect the cardiovascular, gastrointestinal, and other systems, and can threaten patients by causing such as fatal arrhythmia, myocardial infarction, cerebrovascular events, and sudden death [5-7]. PPGLs have the potential for metastases, in the case of metastatic PPGLs, found in the presence of tumors derived from chromaffin cells in non-chromaffin organs at the time of diagnosis or during the follow-up period [8]. According to a recently published study, metastases were already detected in 9.0% of patients with PPGLs at the initial diagnosis, and 9.5% of metastases occurred during the follow-up period [1]. Excess of catecholamine, as well as metastases involve in increased morbidity and mortality in PPGLs patients [9-11]. Therefore, timely and accurate diagnosis and treatment of PPGLs is essential.

In recent years, with the advancement of next-generation sequencing (NGS) technology, the genetic discoveries of PPGLs have increased significantly, and at least 30% of these tumors have been identified as hereditary [12]. Over the past decade, our knowledge in the field of PPGLs has been rapidly expanded and changed by many discoveries in genetics, biochemical, imaging diagnosis, and treatment of these tumors. Therefore, the modifications in the fourth edition of the World Health Organization (WHO) classification in 2017 is primarily based on the novel findings on the clinical behaviors and genetics of adrenal tumors [13]. There have been exponential advances in the genetics of these tumors according to the progress in NGS technology, and in recent years, new susceptible genes with germ-line and somatic mutations have been discovered [12,14,15]. In addition to catecholamines, various products secreted by PPGLs, such as chromogranin A, have begun to be applied as useful biochemical diagnostic markers [16]. Beyond the traditional functional imaging study with $^{123}$I-metaiodobenzylguanidine (MIBG) scintigraphy, the emerged molecular imaging techniques, such as $^{1}$C-hydroxyephedrine positron emission tomography/computed tomography (PET/CT) and gallium 68 ($^{68}$Ga) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-somatostatin receptor analogs (SSA) PET/CT, have
been introduced for the precise diagnosis for localization and staging [17,18].

In accordance with the revised international recommendations and advanced diagnostic techniques, the PPGL task force team has developed the guideline for the diagnosis of PPGLs, regarding controversial issues in South Korea. The following will discuss the changes noted in the new WHO classification and provide updates on genetic, biochemical, and imaging diagnostic approaches of the PPGLs.

**METHODS**

Development of evidence-based recommendations

This guideline was developed by the multidisciplinary committee, which comprises the Korean Endocrine Society, the Korean Surgical Society, the Korean Society of Nuclear Medicine, the Korean Society of Pathologists, the Korean Society of Radiology, and the Korean Society of Laboratory Medicine. The guideline included the most current evidence-based recommendations for diagnosis of PPGLs. The grading system included the following considerations: numbers of well-designed randomized controlled trials, meta-analysis results, cohort studies, patient–control studies, or expert opinion on clinical experiences. The guideline committee’s grading system uses A, B, C, or E to present the evidence level supporting each recommendation, as defined in the previous study (Table 1) [19].

**DISCUSSION OF THE RECOMMENDATIONS**

1. New classification of pheochromocytoma/paraganglioma

Substantial changes have been included regarding the topics of adrenal tumors in the fourth edition of the WHO classification of endocrine tumors published in 2017 compared to the third edition of 2004 [20,21]. In the 2017 version of the WHO classification, information on ‘tumors of the adrenal medulla and extra-adrenal paraganglia’ has been described in an independent chapter and has been separated from the chapter discussing the ‘tumors of the adrenal cortex’ [20]. Table 2 summarizes the WHO classification of tumors of the adrenal medulla and extra-adrenal paraganglia [20].

1.1. All PPGLs are considered to have metastatic potential. The terms “benign” and “malignant” should not be used to distinguish non-metastatic PPGLs from metastatic PPGLs (A).

Prior to the update on adrenal tumors in 2017 WHO of endocrine tumors, PPGLs have traditionally been classified as “malignant” and “benign” based on the presence of distant metastases.

| Table 2. Updated Version of 2017 World Health Organization Classification of Tumors of the Adrenal Medulla and Extra-Adrenal Paraganglia |
|---------------------------------------------------------------|
| Pheochromocytoma                                              |
| Head and neck paraganglioma                                   |
| Sympathetic paraganglioma                                     |
| Neuroblastic tumour of the adrenal gland                      |
| Neuroblastoma                                                 |
| Ganglioneuroblastoma, nodular                                 |
| Ganglioneuroblastoma, intermixed                              |
| Ganglioneuroma                                                 |
| Composite pheochromocytoma                                    |
| Composite paraganglioma                                       |

| Table 1. Summary of Strength of Evidence for Recommendations |
|-------------------------------------------------------------|
| A | When there is a clear rationale for the recommendations: 
When multiple randomized controlled trials that can be generalized because they have sufficient test or meta-analysis results supports a recommendation. |
| B | When there is a reliable basis for the recommendation: 
When reasonable grounds support this through well-performed cohort studies or patient–control group studies. |
| C | When there is a possible basis for the recommendations: 
When relevant grounds are seen through randomized clinical studies or case reports and observational studies carried out in a small institution, despite their inherent unreliability. |
| E | Expert recommendations: 
There is no basis to support the recommendations, but they are supported by expert opinion or expert clinical experience. |

Adapted from Kim et al. [19].
Metastases occur in approximately 5% to 10% of pheochromocytomas [8]. Several relevant indicators based on histopathology, immunohistochemistry (IHC), genetic mutations and molecular biological characteristics such as the Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) grading system, the Grading of Adrenal Pheochromocytoma and Paraganglioma (GAPP), and the composite pheochromocytoma/paraganglioma prognostic score (COPPs) scoring system have been proposed to predict metastatic potential [22-26]. However, these scoring systems is not well-validated for the prediction of the metastatic tumors. Due to the lack of the approved histological system on PPGL’s biological aggressiveness, all PPGLs are considered to have metastatic potential. Therefore, the terms “malignant” and “benign” are abandoned and combined into a single section “pheochromocytoma” in the updated version of WHO classification of endocrine tumors [20]. In addition, in the current version of the WHO classification, “malignant” was replaced with the term “metastatic” to clearly distinguish between locally invasive and distant metastatic PPGLs.

1.2. The TNM staging system should be evaluated in diagnosing PPGLs (A).

The first staging system for PPGL was published by the American Joint Committee on Cancer (AJCC) in 2017. The AJCC TNM (T, size and location of primary tumor; N, regional lymph node metastases; and M, presence and location of distant metastases) staging system helps to make treatment and prognostic related decisions and provides standardized communicative description tools for the tumor. The TNM classification system for PPGLs reflects the prognostic factors that predict the metastases and shorter survival, and these predictors include the large size of the primary tumor (≥5.0 cm), extra-adrenal tumor, and the presence of distant metastases (e.g., bone, liver, lungs, and lymph nodes) (Table 3) [27]. While smaller (<5.0 cm) tumors rarely occur distant metastases, patients with larger (≥5.0 cm) tumors have lower overall survival rates due to the increased risk of distant metastases [28,29]. Therefore, pheochromocytomas are divided into T1 (<5.0 cm) and T2 (≥5.0 cm) according to the tumor size. Tumors with the invasion of surrounding tissues such as liver or kidneys are classified as T3 because they need extensive surgery and usually tend to be more aggressive [30]. Also, the location of the primary tumors is an important predictive factor of metastases. Sympathetic paragangliomas (PGLs) are associated with higher metastatic potential and shorter overall survival rates regardless of the primary tumor size, so these are reflected in T staging [29].

Patients with metastatic PPGLs have high morbidity and mortality rates due to the excessive catecholamines, and patients with metastatic PPGLs have a significantly lower 5-year survival rate compared to patients without metastases (90% vs. 60%) [31,32]. Similarly, a recent nationwide population-based epidemiological study in South Korea showed the hazard ratio for mortality of patients with metastatic PPGLs was twice higher compared to patients without metastatic PPGLs [1]. The common metastatic sites of metastatic PPGLs are the regional and distant lymph nodes, bone, liver, and lungs [33,34]. Among common metastatic sites, bone metastases are known be less aggressive with a longer median overall survival (12 years) compared with non-skeletal metastases (5 to 7.5 years) [35]. Given that the median survival rates differ according to the metastatic sites, M staging of AJCC was determined by the location of the distant metastases [32].

| Table 3. The AJCC Staging System of Pheochromocytoma and Paraganglioma |
|---------------------------------------------------------------|
| **TNM staging** |
| **Primary tumor (pT)** |
| pTX: primary tumor cannot be assessed |
| pT1: pheochromocytoma <5 cm in greatest dimension |
| pT2: pheochromocytoma ≥5 cm or sympathetic paraganglioma |
| pT3: invasion into surrounding tissues (including extra-adrenal adipose) |
| **Regional lymph nodes (pN)** |
| pNX: regional lymph nodes cannot be assessed |
| pN0: no regional lymph node metastasis |
| pN1: regional lymph node metastasis |
| **Distant metastases (pM)** |
| M0: no distant metastasis |
| pM1a: metastasis to bone |
| pM1b: metastasis to non-regional lymph node, liver or lung |
| pM1c: metastasis to bone and multiple other sites |
| **AJCC prognostic stage groups** |
| Stage I: T1 N0 M0 |
| Stage II: T2 N0 M0 |
| Stage III: T1-2 N1 M0 or T3 any N M0 |
| Stage IV: any T any N M1 |

AJCC, American Joint Committee on Cancer; TNM, tumor-node-metastasis. 
*Nonfunctional parasympathetic paragangliomas (arising from the head and neck) are excluded in this staging; Regional lymph nodes includes aortic and retroperitoneal nodes for abdominal and pelvic tumors.
2. Biochemical tests of pheochromocytoma/paraganglioma

2.1. Initial biochemical tests of PPGL should include measurements of plasma free metanephrines or urinary fractionated metanephrines (A).

Evidence of catecholamine excess is an essential prerequisite for the clinical diagnosis of PPGL. Metanephrines are the O-methylated metabolites of epinephrine and norepinephrine. They are produced within the cytoplasm of adrenal chromaffin cells or PPGL tumor cells by catechol-O-methyltransferase. This process occurs continuously and independently from exocytic catecholamine release, which is the theoretical basis of superior sensitivity of measuring metanephrines than catecholamines for the diagnosis of PPGL.

Previous clinical studies consistently reported superior sensitivity and specificity of metanephrines than other biochemical tests for PPGL. One of the early studies, which included 214 pheochromocytoma patients from National Institutes of Health (NIH) and European centers, demonstrated a sensitivity of 99% and specificity of 89% for plasma free metanephrines [36]. The diagnostic performance of plasma free metanephrines was significantly higher than urinary catecholamines or vanillylmandelic acid based on the receiver operating curve analysis. A meta-analysis of the diagnostic accuracy of plasma free metanephrines estimated the pooled sensitivity and specificity as 97% and 94% [37].

Several studies compared the diagnostic accuracy of urinary fractionated metanephrines and plasma free metanephrines. Plasma free metanephrines showed a higher sensitivity and specificity than urinary fractionated metanephrines [36,38-41]. However, the difference was small and not statistically significant. Currently, no priority was recommended between plasma free metanephrines and urinary fractionated metanephrines.

The diagnostic accuracy of metanephrines was also evaluated in Korean PPGL patients. In a single-center study of 28 patients and 156 control subjects, plasma free metanephrines showed sensitivity and specificity of 96% and 76%, respectively. Urinary fractionated metanephrines showed sensitivity and specificity of 96% and 94%, respectively [42]. Another study enrolled patients from two large Korean centers also reported high diagnostic accuracy of urinary fractionated metanephrines [43].

For accurate measurement and interpretation of metanephrines, measurement methods, sampling conditions and cut-offs of the assay should be considered. Liquid chromatography with mass spectrometric or electrochemical detection methods is highly accurate and reproducible with low risk of interference. The position of blood sampling should be considered when interpreting the results of plasma free metanephrines. Previous studies used blood sampling in the supine position. Upright positioning stimulates norepinephrine release and subsequently increases plasma normetanephrine. Seated sampling generally reported higher cut-off for diagnosing PPGL and lower specificity than supine sampling [44]. Thus, supine position is recommended for blood sampling, especially when retesting after equivocal elevation of metanephrines.

2.2. Measurements of urinary dopamine and plasma 3-methoxytyramine are useful for the biochemical diagnosis of PPGLs with predominantly dopamine secretion and/or high risk for metastases (C).

As metanephrines are metabolites of epinephrine and norepinephrine, 3-methoxytyramine is O-methylated metabolite of dopamine produced by catechol-O-methyltransferase. Plasma 3-methoxytyramine level can be elevated in PPGL patients due to the excess production of dopamine. The diagnostic accuracy of plasma 3-methoxytyramine for the diagnosis of overall PPGL is not superior to metanephrines. The addition of plasma 3-methoxytyramine to plasma free metanephrines did not significantly increase the diagnostic accuracy for PPGL [45]. However, for some PPGLs that produce dopamine predominantly, plasma 3-methoxytyramine can provide superior diagnostic utility than metanephrines. Plasma 3-methoxytyramine was elevated in dopamine-producing PGLs by nearly 100-folds, suggesting high discriminative power of plasma 3-methoxytyramine for dopamine-producing PPGLs [46].

Elevated plasma 3-methoxytyramine is associated with a high risk of metastatic PPGL. In a large European cohort of 365 PPGL patients, 105 patients with metastatic PPGL showed significantly higher plasma 3-methoxytyramine and urinary dopamine [47]. The mean plasma 3-methoxytyramine level was higher by nearly 4-folds in metastatic PPGL than non-metastatic PPGL. In addition, succinate dehydrogenase B (SDHB) mutant PPGL showed increased production of dopamine in the tumor metabolomics and had high plasma and urinary dopamine and plasma 3-methoxytyramine levels [48]. SDHB mutation confers a high risk of metastases, which, at least partly, explains the high risk of metastases in PPGL with elevated dopamine and 3-methoxytyramine.

2.3. Chromogranin A can be used as a biomarker for biochemically silent PPGL (PPGL with normal metanephrine, normetanephrine, and 3-methoxytyramine) (C). Chromogranin A serves an important role in the formation of
secretory granules of neuroendocrine cells. Plasma or serum chromogranin A level is elevated in patients with neuroendocrine tumors. Chromogranin A is highly sensitive and specific for PPGLs when differentiating PPGL patients from normal individuals [49,50]. Chromogranin A was still elevated in biochemically silent PPGLs with normal metanephrine, normetanephrine and methoxytyramine [51]. The histologic evaluation in silent PPGLs showed preserved secretory granule without the expression of tyrosine hydroxylase, which explains the molecular mechanism of elevated chromogranin A in biochemically silent PPGLs.

3. Imaging of pheochromocytoma/paraganglioma

3.1. Once there is clear biochemical evidence of a PPGL, anatomic imaging by CT is the first-choice imaging modality to locate PPGLs. MRI is the second-choice imaging method when CT findings are inconclusive or when patients are poor candidate to undergo contrast-enhanced CT (A).

For the localization of PPGLs, both CT and magnetic resonance imaging (MRI) are highly sensitive. CT with contrast provides an excellent detection rate between 88% and 100% [52-54]. Considering that most PPGLs are located in the abdomen, a CT scan of the abdomen and pelvis should be the first anatomical imaging modality. CT is preferred to MRI for the detection of lung metastases, while MRI shows better sensitivity between 90% and 95% for detecting skull base and neck PGLs than CT [55,56]. MRI is also preferred in patients with an allergy to CT contrast agent, and in patients in whom radiation exposure should be limited (i.e., children, pregnant women, patients with known germline mutations, and those with recent excessive radiation exposure) [57].

3.2. Functional imaging is recommended for evaluating disease characteristics and detecting metastases, particularly in patients with a high-risk for metastases and multifocal diseases (e.g., lager tumor size >5.0 cm, extra-adrenal, bilateral, or hereditary) (A).

3.3. We suggest $^{123}$I-MIBG scintigraphy/scintigraphy/single-photon emission computed tomography (SPECT), $^{68}$Ga-DOTA-SSA PET/CT, or Fluorine-18-L-Dihydroxyphenylalanine ($^{18}$F-DOPA) PET/CT as the functional imaging modality according to the genotype, location, availability of radiopharmaceuticals, and clinical situation (B).

In patients with a high-risk for metastatic disease, such as large size of the primary tumor, extra-adrenal, multifocal (except skull base and neck PPGLs), and recurrent disease, the use of functional imaging modalities are suggested for detecting metastases. $^{18}$F-fluorodeoxyglucose (FDG) PET has been used for this purpose; however, other functional imaging is currently recommended as the first choice of image because of its higher sensitivity and specificity [58]. The reported diagnostic performance of each functional modality is different according to disease location, disease extent, and genotype (Table 4).

$^{123}$I/$^{131}$I-MIBG scintigraphy has a comparable sensitivity for pheochromocytoma to fluorine-18-L-dihydroxyphenylalanine ($^{18}$F-DOPA) PET/CT and $^{68}$Ga-DOTA-SSA PET/CT [59-62]. The diagnostic performance is enhanced with use of $^{123}$I-MIBG and single-photon emission computed tomography (SPECT) [62,63]. However, the sensitivity of $^{123}$I-MIBG scintigraphy in PGLs and metastatic PPGLs is relatively suboptimal, particularly for SDHx-related PPGLs [64-67].

$^{68}$Ga-DOTA-SSA PET/CT is the most sensitive tool for detecting PPGLs in patients with unknown genetic status based on a recent systemic review and meta-analysis [68]. The elevated clinical value of $^{68}$Ga-DOTA-SSA PET/CT is also observed in extra-adrenal PGLs and head and neck PGLs [69-71]. Furthermore, $^{68}$Ga-DOTA-SSA PET/CT is preferred in the metastatic PPGLs [72]. In PPGLs with underlying SDHx mutations, $^{68}$Ga-DOTA-SSA PET/CT can be recommended [73]. In contrast to SDHx-related PPGLs, $^{18}$F-DOPA PET/CT showed high tumor uptake in von Hippel-Lindau (VHL), rearranged during transfection (RET), neurofibromatosis 1 (NF1), myc-associated protein X (MAX), hypoxia-inducible factor (HIF) 2A, prolyl hydroxylase (PHD)1/2, and fumarate hydratase (FH) mutated PP-

### Table 4. Diagnostic Performance of Functional Imaging Modalities for Pheochromocytoma and Paraganglioma

|                  | $^{68}$Ga-DOTA-SSA | $^{18}$F-DOPA | $^{18}$F-FDG | $^{123}$I/MIBG |
|------------------|--------------------|---------------|-------------|---------------|
| Detection rate, %| 93.0–100           | 61.4–97.4     | 49.2–85.8   | 6.9–100       |

$^{68}$Ga-DOTA-SSA, gallium 68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin receptor analogs; $^{18}$F-DOPA, fluorine-18-L-fluoro-dihydroxyphenylalanine; $^{18}$F-FDG, $^{18}$F-fluorodeoxyglucose; $^{123}$I-MIBG, $^{123}$I-metaiodobenzylguanidine.
GLs [74,75]. The exact mechanism for this phenotype is currently largely unrevealed, and many of these reports are based on extremely rare cohorts.

Despite the clinical relevance of each functional imaging modality according to disease characteristics and genotypes, the practical availability of radiopharmaceuticals and clinical situation should be considered. \(^{68}\)Ga is produced by a generator system that is affordable only in large centers, whereas \(^{123}\)I/\(^{131}\)I-MIBG, \(^{18}\)F-FDG, and \(^{18}\)F-DOPA are commercially available in many countries including Korea. Additionally, all of the functional imaging modalities are effective despite relative inferiority to another in a specific situation. Therefore, it is recommended to appropriately utilize the recommended first choice or alternative functional imaging modalities that are available for each institution (Fig. 1).

3.4. In PPGL patients planning for \(^{131}\)I-MIBG treatment, \(^{123}\)I-MIBG imaging is necessary for treatment decision and response monitoring. \(^{68}\)Ga-DOTA-SSA PET/CT is necessary in patients with metastatic PPGLs when PRRT is planned (B).

In patients with metastatic PPGLs, targeted radiopharmaceuticals treatment may be considered. In \(^{123}\)I-MIBG scintigraphy-positive metastatic PPGLs, high dose \(^{131}\)I-MIBG therapy can be beneficial [76]. In particular, high-specific-activity \(^{131}\)I-MIBG (Azedra, Progenics Pharms Inc., New York, NY, USA) has received U.S. Food and Drug Administration approval for metastatic or locally aggressive PPGLs, which showed radiographic response rate of 92% and biochemical response of 68% in the phase-II study [77]. Pre- and post-treatment \(^{123}\)I/\(^{131}\)I-MIBG is essential to select appropriate candidate and response monitoring. In patients who are planning peptide receptor radionuclide therapy (PRRT), \(^{68}\)Ga-DOTA-SSA PET/CT should be performed. \(^{177}\)Lu, \(^{90}\)Y, \(^{225}\)Ac-labeled DOTA-D-Phe1-Tyr3-octreotide (TOC) and DOTA-0-Tyr3-octreotate (TATE) is the currently available PRRT as compassionate or off-label use [78,79]. Currently, \(^{177}\)Lu-DOTA-TATE is commercially available in many countries including Korea, although it has not been officially approved for PPGL in most countries due to lack of clinical trials. The overall disease control rate of PRRT is 84%, and the biochemical response rate is between 61% and 64% in a meta-analysis [79]. Thus, it is recommended to consider PRRT in patients with metastatic PPGL who are not eligible for conventional chemotherapy and \(^{131}\)I-MIBG, when effective uptake is observed on

---

**Fig. 1.** Proposed clinical algorithm for nuclear (molecular) imaging studies for pheochromocytoma/paraganglioma. PPGL, pheochromocytoma/paraganglioma; PHEO, pheochromocytoma; HNPGL, head and neck paraganglioma; SDH, succinate dehydrogenase; VHL, von Hippel-Lindau; RET, rearranged during transfection; NF1, neurofibromatosis 1; MAX, myc-associated protein X; HIF2A, hypoxia-inducible factor 2A; PHD1/2, prolyl hydroxylase domain 1/2; FH, fumarate hydratase; \(^{123}\)I-MIBG, \(^{123}\)I-metaiodobenzylguanidine; \(^{68}\)Ga-DOTA-SSA, gallium 68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin receptor analogs; \(^{18}\)F-DOPA, fluorine-18-L-fluorodihydroxyphenylalanine; \(^{18}\)F-FDG, \(^{18}\)F-fluorodeoxyglucose; PRRT, peptide receptor radiotherapy.
4. Pathological grading system of pheochromocytoma/paraganglioma

4.1. The PASS and the GAPP cannot be used to confirm the diagnosis of malignancy (B).

To predict risks for PPGL metastases, two separate histological prediction systems have been established as followed; the PASS grading system and the GAPP (Table 5) [25,26]. First, the earliest grading system for detecting the potential of metastatic behavior of pheochromocytoma was the PASS grading system created by Thompson [26] in 2002. PASS originally designed for pheochromocytomas only incorporates 12 individually histologic features endowed with different points (one or two points), which were based on the occurrence of parameters in a pre-defined metastatic cohort. With a total score of 20 of PASS, a pheochromocytoma is considered as biologically aggressive when applying a cut-off score of ≥4 whereas those with a score <4 are considered not to have metastatic potential [26,80]. The PASS grading system has been validated in previous studies, of which the results were inconsistent [81-83]. These studies generally indicate that the PASS system is of high sensitivity (100%) and low specificity with the potential to correctly “rule in” metastatic pheochromocytomas [58,84]. However, this system also carries its shortcomings. First, it has inter- and intra-observer variations [33]. Second, other important factors such as gene mutation, tumor characteristics, and clinical characteristics of patients were ignored, whereas only histological characteristics were included [58,84]. These advantages have been debated in terms of the clinical value of the PASS grading system, which limited application to all PPGL cases for clinical prognostication [80]. Then, the GAPP was developed by Kimura et al. [25] for both PPGLs, which included some histological features from the PASS and added immunohistochemical (Ki-67 index) and biochemical (catecholamine type) data. The GAPP model stratifies the PPGLs into three classes: well-differentiated

| Table 5. Comparison of Two Systems Predicting Pheochromocytoma and Paraganglioma Metastatic Potential |
|--------------------------------------------------------|--------------------------------------------------------|
| **Parameter**                                           | **PASS (score if present)** | **GAPP (points scored)** |
| Criteria (no. of subject)                              | Only PHEO                  | Both PHEO and PGL        |
| 1. Large nests or diffuse growth (2)                   |                           |                           |
| 2. Central or confluent tumor necrosis (2)             |                           |                           |
| 3. High cellularity (2)                                |                           |                           |
| 4. Cellular monotony (2)                               |                           |                           |
| 5. Tumor cell spindling (2)                            |                           |                           |
| 6. Mitotic figures >3/10 HPF (2)                       |                           |                           |
| 7. Atypical mitotic figure(s) (2)                      |                           |                           |
| 8. Extension into adipose tissue (2)                   |                           |                           |
| 9. Vascular invasion (1)                               |                           |                           |
| 10. Capsular invasion (1)                              |                           |                           |
| 11. Profound nuclear pleomorphism (1)                  |                           |                           |
| 12. Nuclear hyperchromasia (1)                         |                           |                           |
| 1. Histological pattern                               |                           |                           |
| - Zellballen (0)                                      |                           |                           |
| - Large and irregular cell nest (1)                    |                           |                           |
| - Pseudorosette (even focal) (1)                       |                           |                           |
| 2. Cellularity                                         |                           |                           |
| - Low (<150 cells/U) (0)                               |                           |                           |
| - Moderate (150–250 cells/U) (1)                       |                           |                           |
| - High (more than 250 cells/U) (2)                     |                           |                           |
| 3. Comedo necrosis                                    |                           |                           |
| - Absence (0)/Presence (1)                             |                           |                           |
| 4. Vascular or capsular invasion                       |                           |                           |
| - Absence (0)/Presence (1)                             |                           |                           |
| 5. Ki67 labelling index (%)                            |                           |                           |
| - <1 (0)/1–3 (1)>3 (2)                                 |                           |                           |
| 6. Catecholamine type                                  |                           |                           |
| - Epinephrine type (0)                                 |                           |                           |
| - Norepinephrine type (1)                              |                           |                           |
| - Non-functioning type (0)                             |                           |                           |
| Total score                                           | 0–20                      | 0–10                      |
| Risk groups                                           | 0–3: benign fashion       | 0–2: Well-differentiated type |
|                                                    | 4–20: biologically aggressive behavior           | 3–6: Moderately differentiated type |
|                                                    |                                | 7–10: Poorly differentiated type                |
| Sensitivitya                                         | 100%                       | 90%                       |
| Specificitya                                      | 75%                        | 87%                       |

*a* For detection of malignancy.

[^68]: Ga-DOTA-SSA PET/CT.
4.2. The loss of SDHB protein by IHC staining in tumor cells is suggested to detect the presence of germline mutations in one of the SDHx genes. PPGLs associated with SDHB mutation have a high risk of metastases (B).

Pathogenic germline variants in any of the SDHx subunit genes (SDHA/B/C/D) have been implicated in hereditary tumorigenesis of PPGLs [86]. The majority of patients with hereditary PPGL syndromes (30% to 40%) have germline mutations in these SDHx subunit genes [86]. Germline mutations of SDHB have been widely accepted as a high-risk factor for metastases, leading to metastatic PPGLs in 40% or more of affected patients [57,87,88]. Furthermore, SDHB germline mutation is a poor prognostic factor in patients with metastatic PPGLs [11]. In terms of the 5-year probability of survival after the diagnosis of the first metastases were 0.36 (0.15 to 0.57) in SDHB mutation carriers and 0.67 (0.47 to 0.81) in the absence of SDHB mutation (relative risk, 2.6; \( P = 0.019 \)) [24]. SDHB mutation carriers also have a shorter median survival of 42 months, compared to 244 months for SDHB mutation non-carriers. This shorter median survival was significantly associated with the presence of SDHB mutations independent of age at diagnosis.

Germline mutations in any of these SDHx genes lead to destabilization of the SDH protein complex and loss of SDHB expression at IHC. Therefore, loss of SDHB IHC staining in tumor tissue suggests the presence of germline mutations in one of the SDHx genes with 100% sensitivity and 84% specificity [80,89,90]. Several studies have reported that a combination of biochemical, histological, and SDHB IHC might be useful for predicting metastatic PPGLs [24,25]. One of them was the modified GAPP (M-GAPP) proposed by Koh et al. [24] in 2017. Furthermore, SDHB IHC test is technically easy and cost-effective because of its simplicity of the standard procedure and data interpretation. Hence, it can be routinely performed in all PPGLs, even in the absence of familial or clinical indications for a specific form of inherited PPGL. Therefore, it is necessary to identify SDHx (SDHB, SDHC, and SDHD) germline mutation by the loss of SDHB IHC staining in all patients with PPGLs [91].

5. Genetic testing for pheochromocytoma/paraganglioma

5.1. Genetic testing is recommended in all patients diagnosed with PPGLs (A).

PPGLs have striking characteristics regarding the importance of genetic testing, which are their high heritability and genetic heterogeneity [92]. PPGLs are the most frequently heritable tumors in humans, with at least 30% to 40% of inherited forms of the disease [93]. For this reason, it is recommended that all patients are ‘engaged in shared decision making’ and ‘considered’ for genetic testing, respectively [57,94]. There are several reasons genetic testing should be considered in all patients with PPGLs. First of all, more than one third of all patients with PPGLs have disease-causing germline mutation in PPGL susceptibility genes because of their strong genetic determinism [95]. Second, about 40% or more of patients with SDHB mutation have metastatic phenotype as the principal predictor of malignancy in PPGL patients [57,93,94]. Third, patients with genetic or syndromic PPGL have higher risks in development for PPGL complications compared to those with apparently sporadic disease [94,96]. Fourth, about 11% to 13% of patients with apparently sporadic PPGLs such as single benign PPGL without a family history have a mutation in susceptibility genes according to a meta-analysis [97]. Lastly, the identification of the genetic mutation in the proband may have implications for their family members related to the necessity of surveillance [98].

5.2. Genetic testing should be also considered for first-degree relatives of patients with hereditary PPGLs (B).

As mentioned in the previous section 5.1, PPGLs are the most heritable tumors with syndromic clinical features such as NF1, VHL, multiple endocrine neoplasia type 2 (MEN2), or paraganglioma syndrome (PGL). These pheochromocytoma-associated syndromes usually have a higher frequency of family history through the mostly autosomal dominant transmission [99]. For this reason, the Endocrine Society also recommends directly targeted germline mutation testing beyond sequential genetic testing in patients with PPGLs who have a positive family his-
5. Validated targeted NGS is a preferred method for the genetic diagnosis of PPGLs (B).

Since 1990, germline mutation in a dozen PPGL susceptibility genes have been reported [57,95]. Moreover, as techniques for genetic testing have been advanced, higher mutation discovery rates and a better understanding of the clinical phenotypes of PPGLs have been achieved [93]. After the Endocrine Society proposed a clinical feature-driven diagnostic algorithm for priorities for specific genetic testing for PPGL, the advent of NGS methods offers a single assay for the screening of all PPGL susceptibility genes [100]. Therefore, decision algorithms for PPGL genetic testing has been changed from ‘from the patient to the candidate genes’ into ‘from the mutated genes to the affected patient’ [95]. Likewise, the implementation of NGS has been a paradigm shift in genetics research of PPGLs [92]. Accordingly, the NGS in PPGL (NGSnPPGL) study group recommended genetic testing should be performed in all patients with PPGLs independent of clear family history [92]. They preferred targeted NGS as a method for genetic diagnosis of PPGLs with blood (fresh collected within 7 days or frozen) or a frozen leukocyte pellet. The suggested targeted panels should include coding exons and intron boundaries of the targeted genes. As in conventional genetic testing, whenever possible, confirmation of the NGS-identified variant in a separate aliquot of the patient’s DNA is highly recommended by using an orthogonal method such as Sanger sequencing [92].

5.4. We recommend targeted NGS panels of gene sets based on the current level of evidence of their pathogenic driver status: 10 basic panel (FH, MAX, NF1, RET, SDHA, SDHB, SDHC, SDHD, TMEM127, VHL) and five extended panel (egl-9 family hypoxia inducible factor 1/ prolyl hydroxylase domain 2 [EGLN1/PHD2], endothelial PAS domain-containing protein 1 [EPAS1], kinesin family member 1B [KIF1B], MET, SDHAF2) (C).

The NGSnPPGL study group proposed three sets of gene panels for the diagnosis of PPGLs; basic (evidence level 3 and 4 for germline mutations; including 10 genes such as FH, MAX, NF1, RET, SDHA, SDHB, SDHC, SDHD, TMEM127, and VHL), extended (evidence level 2 for germline mutations; including five more genes such as EGLN1/PHD2, EPAS HIF2A, KIF1B, MET, and SDHAF2), and comprehensive panels (all somatic mutations and all levels of evidence; extended genes added to 12 more genes including alpha thalassemia/mental retardation syndrome X-linked [ATRX], v-raf murine sarcoma viral oncogene homolog B1 [BRAF], cyclin dependent kinase inhibitor 2A [CDKN2A], EGLN2/PHD1, fibroblast growth factor receptor 1 [FGFR1], H3 histone, family 3A [H3F3A], Harvey rat sarcoma viral oncogene homolog [HRAS], isocitrate dehydrogenase 2 [IDH2], lysine [K]-specific methyltransferase 2D [KMT2D], malate dehydrogenase 2 [MDH2], MER proto-oncogene, tyrosine kinase [MERTK], and tumor protein p53 [TP53]) [92].

Herein, they modified ClinVar review status to adapt for their consensus statement on PPGLs driver genes. They used five levels (evidence level 0–5) based on numbers of applicable sources; level 0 with not applicable; level 1 with single source; level 2 as two or more sources without functional validation; level 3 with two or more sources with some functional validation; and level 4 with established evidence from clinical, genetic, computational prediction as well as functional evidence and/or analysis of population frequency. A study about the diagnostic methods of PPGLs demonstrated that NGS assay significantly improved the performances of PPGL genetic testing compared with conventional methods with a higher rate of the identified mutation [101]. From that study, Ben Aim et al. [101] designed and suggested their custom multigene panel, ‘MAST-ER Plus SDHv2,’ including 17 PPGL genes; VHL, NF1, RET, SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127, FH, MAX, EPAS1, EGLN1, EGLN2, MDH2, ATRX, and HRAS. Unfortunately, there are limited data on genetic studies of PPGL in Korea [102]. Recently, a study with the largest number of Korean PPGL patients (n=161) reported that approximately 21% of sporadic PPGLs without any family history still harbored germline mutation of the PPGL-related genes [103]. This could be a convincing evidence for performing targeted NGS study in Korean patients with PPGLs like other ethnic groups. Another recent published data also reported genetic analysis and clinical characteristics of PPGLs in Korea [104]. In this study, among 57 patients with PPGLs, 28 different germline mutations were identified in 11 susceptibility genes (EPAS1, KIF1B, MAX, NF1, RET, SDHA, SDHB, SDHC, SDHD, TMEM127, and VHL). The prevalence of germline mutation was 32.6%, and the most frequently mutated genes were SDHB (n=11, 31.4%) fol-
lowed by RET (n=8, 22.3%), VHL (n=6, 17.1%), NF1 (n=2, 5.7%), and EPAS1 (n=2, 5.7%) [104].

Taking all these considerations into account, we recommend two sets of gene panels (basic and extended) based on the current level of evidence of their pathogenic driver status, which adopted from the consensus statement of NGS based diagnostic testing of hereditary PPGLs by the NGSnPPGL study group (Table 6) [92]. When the primary mutation is not found in targeted NGS, comprehensive genetic studies such as whole-exome sequencing or whole-genome sequencing can be further considered to improve the understanding of the pathogenicity in any possible variants whenever possible [92]. A recent study performing WES in 36 patients with PPGL who had negative tests from previous Sanger sequencing or targeted gene panel revealed that two more likely pathogenic variants were additionally detected [105].

CONCLUSIONS

As a result of overarching research, PPGLs has been known as the representative hereditary tumor and newly classified as a malignant tumor. Also, great progress has been made regarding biochemical tests, functional imaging, and genetic testing. Accordingly, we can diagnose PPGLs more appropriately, detect multifocal or metastatic lesions, and predict prognosis better. We hope that this position statement provides the current knowledge and be helpful in clinical practice.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This research was supported by the Korean Endocrine Society. We would like to thank the Korean Endocrine Society, the Korean Surgical Society, the Korean Society of Nuclear Medicine, the Korean Society of Pathologists, and the Korean Society of Laboratory Medicine.

ORCID

Eu Jeong Ku https://orcid.org/0000-0001-5533-4989
Kyoung Jin Kim https://orcid.org/0000-0001-7925-2515
Chong Hwa Kim https://orcid.org/0000-0002-4563-7772
Eun Jig Lee https://orcid.org/0000-0003-3231-9887

REFERENCES

1. Kim JH, Moon H, Noh J, Lee J, Kim SG. Epidemiology and prognosis of pheochromocytoma/paraganglioma in Korea: a nationwide study based on the National Health Insurance Service. Endocrinol Metab (Seoul) 2020;35:157-64.
2. Berends AMA, Buitenwerf E, de Krijger RR, Veeger NJGM, van der Horst-Schrivers ANA, Links TP, et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review. Eur J Intern Med 2018;51:68-73.
3. Barontini M, Levin G, Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann N Y Acad Sci 2006;1073:30-7.
4. Beltsevich DG, Kuznetsov NS, Kazaryan AM, Lysenko MA. Pheochromocytoma surgery: epidemiologic peculiarities in children. World J Surg 2004;28:592-6.
5. Pacak K, Taieb D. Pheochromocytoma (PHEO) and paraganglioma (PGL). Cancers (Basel) 2019;11:1391.
6. Bisogni V, Petramala L, Oliviero G, Bonvicini M, Mezzadri M, Olmati F, et al. Analysis of short-term blood pressure variability in pheochromocytoma/paraganglioma patients. Cancers (Basel) 2019;11:658.

7. Kvasnicka J, Zelinka T, Petrak O, Rosa J, Strauch B, Kratka Z, et al. Catecholamines induce left ventricular subclinical systolic dysfunction: a speckle-tracking echocardiography study. Cancers (Basel) 2019;11:318.

8. Kim KY, Kim JH, Hong AR, Seong MW, Lee KE, Kim SJ, et al. Disentangling of malignancy from benign pheochromocytomas/paragangliomas. PLoS One 2016;11:e0168413.

9. van Hulstijn LT, Louise A, Havekes B, Kaptein AA, Jansen JC, Hes FJ, et al. Quality of life is decreased in patients with paragangliomas. Eur J Endocrinol 2013;168:689-97.

10. Timmers HJ, Brouwers FM, Hermus AR, Sweep FC, Verhofstad AA, Verbeek AL, et al. Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. Endocr Relat Cancer 2008;15:1127-33.

11. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007;92:3822-8.

12. Pillai S, Gopalan V, Smith RA, Lam AK. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. Crit Rev Oncol Hematol 2016;100:190-208.

13. Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO classification of tumours: pathology and genetics of tumours of endocrine organs. 4th ed. Lyon: IARC Press; 2017.

14. Gieldon L, William D, Hackmann K, Jahn W, Jahn A, Wagger J, et al. Optimizing genetic workup in pheochromocytoma and paraganglioma by integrating diagnostic and research approaches. Cancers (Basel) 2019;11:809.

15. Pillai S, Gopalan V, Lo CY, Liew V, Smith RA, Lam AK. Silent genetic alterations identified by targeted next-generation sequencing in pheochromocytoma/paraganglioma: a clinicopathological correlations. Exp Mol Pathol 2017;102:41-6.

16. Angelouisi A, Peppa M, Chrisoulidou A, Alexandraki K, Berthon A, Fauz FR, et al. Malignant pheochromocytomas/paragangliomas and ectopic hormonal secretion: a case series and review of the literature. Cancers (Basel) 2019;11:724.

17. Vyakaranam AR, Crona J, Norlen O, Hellman P, Sundin A. 11C-hydroxy-ephedrine-PET/CT in the diagnosis of pheochromocytoma and paraganglioma. Cancers (Basel) 2019;11:847.

18. Chang CA, Pattison DA, Tothill RW, Kong G, Akhurst TJ, Hicks RJ, et al. (68)Ga-DOTATATE and (18)F-FDG PET/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging 2016;16:22.

19. Kim JH, Chae HW, Chin SO, Ku CR, Park KH, Lim DJ, et al., Diagnosis and treatment of growth hormone deficiency: a position statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology. Endocrinol Metab (Seoul) 2020;35:272-87.

20. Lam AK. Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr Pathol 2017;28:213-27.

21. DeLellis RA, Lloyd RV, Heitz PU, Eng C. WHO classification of tumours: pathology and genetics of tumours of endocrine organs. 3rd ed. Lyon: IARC; 2004.

22. Pierre C, Agopiantz M, Brunaud L, Battaglia-Hsu SF, Max A, Pouget C, et al. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas. Virchows Arch 2019;474:721-34.

23. Cho YY, Kwak MK, Lee SE, Ahn SH, Kim H, Suh S, et al. A clinical prediction model to estimate the metastatic potential of pheochromocytoma/paraganglioma: ASES score. Surgery 2018;164:511-7.

24. Koh JM, Ahn SH, Kim H, Kim BJ, Sung TY, Kim YH, et al. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One 2017;12:e0187398.

25. Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2014;21:405-14.

26. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 2002;26:551-66.

27. Edge SB, Amin MB, Meyer LR, Gress DM; American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.

28. Plouin PF, Fitzgerald P, Rich T, Ayala-Ramirez M, Perrier ND, Baudin E, et al. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm Metab Res
29. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 2011;96:717-25.
30. Roman-Gonzalez A, Jimenez C. Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials. Curr Opin Endocrinol Diabetes Obes 2017;24:174-83.
31. Adjalle R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res 2009;41:687-96.
32. Goldstein RE, O’Neill JA Jr, Holcomb GW 3rd, Morgan WM 3rd, Neblett WW 3rd, Oates JA, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999;229:755-64.
33. Ayala-Ramirez M, Palmer JL, Hofmann MC, de la Cruz M, Moon BS, Waguespack SG, et al. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab 2013;98:1492-7.
34. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002;287:1427-34.
35. Chen Y, Xiao H, Zhou X, Huang X, Li Y, Xiao H, et al. Accuracy of plasma free metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review and meta-analysis. Endocr Pract 2017;23:1169-77.
36. Unger N, Hinrichs J, Deutschbein T, Schmidt H, Walz MK, Mann K, et al. Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass. Exp Clin Endocrinol Diabetes 2012;120:494-500.
37. Grouzmann E, Drouard-Troalen L, Baudin E, Plouin PF, Muller B, Grand D, et al. Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma. Eur J Endocrinol 2010;162:951-60.
38. Hickman PE, Leong M, Chang J, Wilson SR, McWhinney B. Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of pheochromocytoma. Pathology 2009;41:173-7.
39. Unger N, Pitt C, Schmidt IL, Walz MK, Schmid KW, Philipp T, et al. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol 2006;154:409-17.
40. Kim HJ, Lee JI, Cho YY, Lee SY, Kim JH, Jung BC, et al. Diagnostic accuracy of plasma free metanephrines in a seated position compared with 24-hour urinary metanephrines in the investigation of pheochromocytoma. Endocr J 2015;62:243-50.
41. Cho YY, Song KH, Kim YN, Ahn SH, Kim H, Park S, et al. Symptom-dependent cut-offs of urine metanephrines improve diagnostic accuracy for detecting pheochromocytomas in two separate cohorts, compared to symptom-independent cut-offs. Endocrine 2016;54:206-16.
42. Lenders JW, Willemsen JJ, Eisenhofer G, Ross HA, Pacak K, Timmers HJ, et al. Is supine rest necessary before blood sampling for plasma metanephrines? Clin Chem 2007;53:352-4.
43. Rao D, Peitzsch M, Prejblisz A, Hanus K, Fassnacht M, Beuschlein F, et al. Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. Eur J Endocrinol 2017;177:103-13.
44. Eisenhofer G, Goldstein DS, Sullivan P, Csako G, Brouwers FM, Lai EW, et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 2005;90:2068-75.
45. Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 2012;48:1739-49.
46. Algeciras-Schimnich A, Preissner CM, Young WF Jr, Singh...
Ku EJ, et al.

RJ, Grebe SK. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab 2008;93:91-5.

50. Grossrubatscher E, Dalino P, Vagnati F, Gambacorta M, Pugliese R, Boniardi M, et al. The role of chromogranin A in the management of patients with pheochromocytoma. Clin Endocrinol (Oxf) 2006;65:287-93.

51. Timmers HJ, Pacak K, Huynh TT, Abu-Asab M, Tsokos M, Merino MJ, et al. Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. J Clin Endocrinol Metab 2008;93:4826-32.

52. Lumachi F, Tregaglia A, Zucchetta P, Cristina Marzola M, Cecchin D, Grassetto G, et al. Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study. Nucl Med Commun 2006;27:583-7.

53. Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, et al. Iodine-131-metiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 1993;34:173-9.

54. Welch TJ, Sheedy PF 2nd, van Heerden JA, Sheps SG, Hattery RR, Stephens DH. Pheochromocytoma: value of computed tomography. Radiology 1983;148:501-3.

55. van Gils AP, van der Mey AG, Hoogma RP, Falke TH, Moolenaar AJ, Pauwels EK, et al. Iodine-123-metiodobenzylguanidine scintigraphy in patients with chemodectomas of the head and neck region. J Nucl Med 1990;31:1147-55.

56. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, Halimi P, et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EV A Investigators. J Clin Endocrinol Metab 2013;98:E162-73.

57. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:1915-42.

58. Wang Y, Li M, Deng H, Pang Y, Liu L, Guan X. The systems of metastatic potential prediction in pheochromocytoma and paraganglioma. Am J Cancer Res 2020;10:769-80.

59. Archier A, Varoquaux A, Garrigue P, Montava M, Guerin C, Gabriel S, et al. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging 2016;43:1248-57.

60. Wiseman GA, Pacak K, O’Dorisio MS, Neumann DR, Waxman AD, Mankoff DA, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med 2009;50:1448-54.

61. Bhatia KS, Ismail MM, Sahdev A, Rockall AG, Hogarth K, Canizales A, et al. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal pheochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) 2008;69:181-8.

62. Rufini V, Treglia G, Castaldi P, Perotti G, Giordano A. Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma: a systematic review. Q J Nucl Med Mol Imaging 2013;57:122-33.

63. Taieb D, Hicks RJ, Hindie E, Guillet BA, Avram A, Ghedini P, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging procedure standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2019;46:2112-37.

64. Milardovic R, Corssmit EP, Stokkel M. Value of 123I-MIBG scintigraphy in paraganglioma. Neuroendocrinology 2010;91:94-100.

65. Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab 2009;94:3922-30.

66. Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurova I, et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 2008;49:1613-9.

67. Fonte JS, Robles JF, Chen CC, Reynolds J, Whatley M, Ling A, et al. False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer 2012;19:83-93.

68. Han S, Suh CH, Woo S, Kim YJ, Lee JJ. Performance of
Diagnosis for Pheochromocytoma and Paraganglioma

68Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis. J Nucl Med 2019;60:369-76.

69. Kroiss A, Shulkin BL, Uprimny C, Frech A, Gasser RW, Url C, et al. (68)Ga-DOTATOC PET/CT provides accurate tumor extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT. Eur J Nucl Med Mol Imaging 2015;42:33-41.

70. Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, et al. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging 2013;40:1800-8.

71. Janssen I, Chen CC, Taieb D, Patronas NJ, Millo CM, Adams KT, et al. 68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI. J Nucl Med 2016;57:186-91.

72. Janssen I, Chen CC, Millo CM, Ling A, Taieb D, Lin FI, et al. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2016;43:1784-91.

73. Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, Herscovitch P, et al. Superiority of [68Ga]DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res 2015;21:3888-95.

74. Taieb D, Jha A, Guerin C, Pang Y, Adams KT, Chen CC, et al. 18F-FDOPA PET/CT imaging of MAX-related pheochromocytoma. J Clin Endocrinol Metab 2018;103:1574-82.

75. Janssen I, Chen CC, Zhuang Z, Millo CM, Wolf KJ, Ling A, et al. Functional imaging signature of patients presenting with polycythemia/paraganglioma syndromes. J Nucl Med 2017;58:1236-42.

76. van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP, (131)I-MIBG therapy for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf) 2014;80:487-501.

77. Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. J Nucl Med 2019;60:623-30.

78. Ballal S, Yadav MP, Bal C, Sahoo RK, Tripathi M. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging 2020;47:934-46.

79. Satapathy S, Mittal BR, Bhansali A. Peptide receptor radio-nuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2019;91:718-27.

80. Kimura N, Takekoshi K, Naruse M. Risk stratification on pheochromocytoma and paraganglioma from laboratory and clinical medicine. J Clin Med 2018;7:242.

81. Kulkarni MM, Khandeparkar SG, Deshmukh SD, Karekar RR, Gaopande VL, Joshi AR, et al. Risk stratification in paragangliomas with PASS (Pheochromocytoma of the Adrenal Gland Scaled Score) and immunohistochemical markers. J Clin Diagn Res 2016;10:EC01-4.

82. Szalat A, Fraenkel M, Doviner V, Salmon A, Gross DJ. Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center. Endocrine 2011;39:160-6.

83. Agarwal A, Mehrrota PK, Jain M, Gupta SK, Mishra A, Chand G, et al. Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy? World J Surg 2010;34:3022-8.

84. Stemman A, Zedienius J, Juhlin CC. The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas: a meta-analysis and systematic review of the literature. Cancers (Basel) 2019;11:225.

85. Wachtel H, Hutchens T, Baraban E, Schwartz LE, Montone K, Baloch Z, et al. Predicting metastatic potential in pheochromocytoma and paraganglioma: a comparison of PASS and GAPP scoring systems. J Clin Endocrinol Metab 2020;105:e4661-70.

86. MacFarlane J, Seong KC, Bisambar C, Madhu B, Allinson K, Marker A, et al. A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: beyond pheochromocytoma and paraganglioma. Clin Endocrinol (Oxf) 2020;93:528-38.

87. Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the pheochromocytoma-paraganglioma syndromes. J Intern Med 2009;266:19-42.

88. Brouwers FM, Eisehnofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, et al. High frequency of SDHB germline
mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 2006;91:4505-9.
89. Papathomas TG, Oudijk L, Persu A, Gill AJ, van Nederveen F, Tischler AS, et al. SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy. A multinational study of the European Network for the Study of Adrenal Tumors (ENS@T). Mod Pathol 2015;28:807-21.
90. van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, et al. An immunohistochemical procedure to detect patients with paraganglioma and pheochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009;10:764-71.
91. Lee H, Jeong S, Yu Y, Kang J, Sun H, Rhee JK, et al. Risk of metastatic pheochromocytoma and paraganglioma in SDHx mutation carriers: a systematic review and updated meta-analysis. J Med Genet 2020;57:217-25.
92. NGS in PPGL (NGSnPPGL) Study Group, Toledo RA, Burnichon N, Cascon A, Benn DE, Bayley JP, et al. Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary pheochromocytomas and paragangliomas. Nat Rev Endocrinol 2017;13:233-47.
93. Buffet A, Burnichon N, Favier J, Gimenez-Roqueplo AP. An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab 2020;34:101416.
94. Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, et al. European Society of Endocrinology clinical practice guideline for long-term follow-up of patients operated on for a pheochromocytoma or a paraganglioma. Eur J Endocrinol 2016;174:G1-10.
95. Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and pheochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol 2015;11:101-11.
96. Buffet A, Ben Aim L, Leboulleux S, Drui D, Vezzosi D, Libe R, et al. Positive impact of genetic test on the management and outcome of patients with paraganglioma and/or pheochromocytoma. J Clin Endocrinol Metab 2019;104:1109-18.
97. Brito JP, Asi N, Bancos I, Gionfriddo MR, Zeballos-Palacios CL, Leppin AL, et al. Testing for germline mutations in sporadic pheochromocytoma/paraganglioma: a systematic review. Clin Endocrinol (Oxf) 2015;82:338-45.
98. Muth A, Crona J, Gimm O, Elmgren A, Filipsson K, Stenmark Askmalm M, et al. Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. J Intern Med 2019;285:187-204.
99. Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med 2019;381:552-65.
100. Johmanova I, Pacak K. Genomic landscape of pheochromocytoma and paraganglioma. Trends Cancer 2018;4:6-9.
101. Ben Aim L, Pigny P, Castro-Vega LJ, Buffet A, Amar L, Bertherat J, et al. Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. J Med Genet 2019;56:513-20.
102. Kim JH, Seong MW, Lee KE, Choi HJ, Ku EJ, Bae JH, et al. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea. Clin Genet 2014;86:482-6.
103. Kim JH, Kim MJ, Kong SH, Kim SJ, Kang H, Shin CS, et al. Characteristics of germline mutations in Korean patients with pheochromocytoma/paraganglioma. J Med Genet 2020 Nov 20 [Epub]. https://doi.org/10.1136/jmedgenet-2020-107102.
104. Choi H, Kim KJ, Hong N, Shin S, Choi JR, Kang SW, et al. Genetic analysis and clinical characteristics of hereditary pheochromocytoma and paraganglioma syndrome in Korean population. Endocrinol Metab (Seoul) 2020;35:858-72.
105. Seo SH, Kim JH, Kim MJ, Cho SI, Kim SJ, Kang H, et al. Whole exome sequencing identifies novel genetic alterations in patients with pheochromocytoma/paraganglioma. Endocrinol Metab (Seoul) 2020;35:909-17.